The application of PET imaging has shown that the response of pancreatic ductal adenocarcinoma after neoadjuvant treatment has changed from morphological assessment to metabolic assessment, especially with the proposal of PET/MRI, playing an important role in predicting treatment outcomes and clinical decision making in these patients. However, due to lack of data, the results need to be further studied.

Previously, the treatment for resectable pancreatic ductal carcinoma was surgery, followed by adjuvant chemotherapy. In 2008, a large retrospective study showed that adjuvant treatment of neoplasia after surgery had a survival advantage over preoperative surgery with or without adjuvant therapy, suggesting the role of adjuvant therapy. adjuvant neoplasia in the treatment of reversible pancreatic ductal carcinoma.